Patients with infectious illnesses frequently have signs and symptoms that are indicative of a disease but that are not unique enough to clinically distinguish what pathogen is making them ill.
Patients can present with general, non-specific symptoms such as cough, myalgia and headache. The lack of a clear diagnosis results in broad treatment, extensive monitoring and possibly unnecessary interventions.
With syndromic testing, results for multiple pathogens are delivered at once. And compared to traditional methods, it can provide results faster. The benefits of syndromic testing extend through the lab, hospital and to the patients.
Join Dr. Josep Pareja for an interactive webinar on the value of syndromic testing for infectious disease diagnostics.
Date and time: Tuesday, June 22, 13:00 CET/14:00 Helsinki time
Title: Benefits of syndromic testing in infectious disease diagnostics – QIAstat-Dx test results in clinical decision making
Speaker: Dr. Josep Pareja, Director Medical Affairs, QIAGEN
A patient may have the flu. A cold. Or they may have been exposed to COVID-19. How can you get results that patients need faster? The QIAstat-Dx Respiratory SARS-CoV-2 Panel gets you results for 21 respiratory targets, including SARS-CoV-2, in about an hour.
Before the COVID-19 pandemic, the majority of respiratory illnesses were caused by the seasonal circulation of common pathogens, including influenza virus. Given the uncertainty surrounding respiratory infections in the future, rapid detection and differential of respiratory viruses through syndromic testing will be essential. Read a piece from our medical affairs team on the future of syndromic testing beyond COVID-19.